Oral Thin Film Drugs Market

Increasing demand for oral thin film drugs delivery systems to enhance the market growth

Oral thin film drug delivery systems are becoming more popular due to their advantages over conventional drug delivery systems, including their larger surface area, precision medication, and pleasant color and flavor. Thin-film drugs are said to be the preferred choice of patients and doctors as they are more patient-friendly and provide high-quality results. Oral thin film medications are accessible to store and transport and have high patient compliance. Moreover, these provide precise and accurate dosing while producing the desired effective result. As a result, the market for thin film drug delivery systems has experienced significant growth.

High acceptance and impressive benefits have propelled the oral thin film drugs market revenue.

Several factors influence the market CAGR of oral thin film drugs. However, improvements in this novel drug delivery are the main factor predicted to drive the market. Due to its growing popularity, numerous businesses worldwide are concentrating their investments on this new method of drug delivery. Key startup companies primarily focus on oral thin-film drug delivery route options for cannabis-based drugs. For example, XPhyto Pharma is working on 13 drugs that will be delivered via thin film. All its products are undergoing Phase II clinical trials in European nations as of February 2021.

The Global Oral Thin Film Drugs Market Industry is projected to experience substantial growth over the next decade. With an estimated market value of 4.05 USD Billion in 2024, the industry is expected to expand to 9.18 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate of 7.72% from 2025 to 2035. Such projections highlight the increasing acceptance and integration of oral thin films in various therapeutic areas, driven by factors such as patient preference, technological advancements, and regulatory support. The market's expansion reflects a broader trend towards innovative drug delivery solutions.

The Global Oral Thin Film Drugs Market Industry is witnessing an expansion in therapeutic applications, which is a key market driver. Originally limited to certain therapeutic areas, oral thin films are now being explored for a broader range of conditions, including pain management, mental health disorders, and infectious diseases. This diversification of applications is likely to attract a wider audience, including healthcare providers and patients seeking alternative delivery methods. The ongoing research and development efforts in this area suggest a promising future for oral thin films, potentially leading to increased market penetration and growth.

The increasing prevalence of chronic diseases globally is a significant driver for the Global Oral Thin Film Drugs Market Industry. Conditions such as diabetes, hypertension, and cardiovascular diseases require consistent medication adherence, which oral thin films can facilitate. These films offer a practical solution for patients who may struggle with traditional dosage forms. The convenience of oral thin films is expected to enhance patient compliance, thereby improving health outcomes. This trend aligns with the projected compound annual growth rate of 7.72% from 2025 to 2035, indicating a robust market response to the rising demand for effective chronic disease management.

Innovations in drug formulation technology are driving the Global Oral Thin Film Drugs Market Industry forward. Advances in polymer science and manufacturing processes have enabled the development of films that can effectively deliver a wide range of therapeutic agents, including those that are poorly soluble. These technological improvements not only enhance bioavailability but also allow for the incorporation of taste-masking agents, making medications more palatable. As a result, the market is likely to expand significantly, with projections indicating a growth to 9.18 USD Billion by 2035, underscoring the impact of these advancements on patient adherence and overall treatment outcomes.

The Global Oral Thin Film Drugs Market Industry is experiencing a notable shift towards patient-centric drug delivery systems. Patients increasingly prefer formulations that are easy to administer, particularly those that dissolve quickly and do not require water. This trend is particularly evident in pediatric and geriatric populations, where swallowing difficulties are common. As a result, oral thin films are gaining traction due to their convenience and ease of use. The market is projected to reach 4.05 USD Billion in 2024, reflecting a growing acceptance of these innovative delivery methods among healthcare providers and patients alike.

Regulatory bodies are increasingly recognizing the potential of innovative drug delivery systems, including oral thin films, which is positively influencing the Global Oral Thin Film Drugs Market Industry. Initiatives aimed at expediting the approval process for novel formulations encourage pharmaceutical companies to invest in research and development. This regulatory support not only fosters innovation but also enhances market entry for new products. As a result, the industry is likely to witness a surge in new product launches, further driving market growth. The favorable regulatory landscape is expected to contribute to the overall expansion of the market in the coming years.

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Oral Thin Film Drugs market accounted for USD 1.55 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. The key factors driving the market in the region are higher penetration of oral thin film drugs, product availability, and the presence of a substantial of suppliers compared to the other regional areas.

Moreover, the rising prevalence of schizophrenia in developed countries such as the United States is expected to fuel regional market growth in the coming years.

Further, the major countries studied in the market report are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3:  ORAL THIN FILM DRUGS MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, Market Research Future Database, and Analyst Review

European oral thin film drugs market accounts for the second-largest market share. Numerous elements, including the rising incidence of Parkinson's disease, impact the market's expansion in Europe. Moreover, more extensive research and development activities on thin-film drugs are expected to propel market growth in European countries. In addition, increased European government funding for innovative drug delivery models is expected to drive the oral thin film drugs industry in the coming years.

Further, the German market of oral thin film drugs held the largest market share, and the UK market of oral thin film drugs was the fastest-growing market in the European region.

The Asia-Pacific Oral Thin Film Drugs Market is expected to grow at the fastest CAGR from 2022 to 2030. Factors such as a larger senior patient pool, rising healthcare spending, and improved infrastructure support market growth in this region. An increase in awareness of thin-film therapeutic applications is expected to propel the market during the forecast timeframe. Other factors driving the regional development of the oral thin film drugs industry include key product launches, a higher concentration of market players or manufacturers, acquisitions, partnerships among significant players, and an increase in cases of target diseases in the region.

Moreover, China’s market of oral thin film drugs held the largest market share, and the Indian market of oral thin film drugs was the fastest-growing market in the Asia-Pacific region.

Major market players in the oral thin film drugs industry are investing in the research and development of fast-dissolving oral thin film drugs to improve their competitive advantage by introducing new platform technologies, including soluleaves, XGEL, and waferTab. R&D contributes to developing novel drug delivery solutions that are more convenient, beneficial, and efficient. A robust pipeline of molecules, contractual agreements, mergers & acquisitions, and unique product launches are key market development strategies major market players use to increase customer reach.

Companies are rushing to develop and launch new products to increase their market share. The oral thin film drugs market major players such as IntelGenx Corp., C.L. Pharma, CURE Pharma, ZIM Laboratories Ltd, and others are working to increase market demand by investing heavily in research and development activities. Manufacturing companies locally to cut operating costs is one of the vital business strategies manufacturers use in the oral thin film drugs industry to benefit customers and expand the international market sector.

CURE Pharmaceutical is an advanced drug delivery, and development firm focused on enhancing drug efficacy, safety, and patient experience through patented technology drug dosage forms and delivery methods. CURE has an industry-leading full-service cGMP manufacturing facility. It is a leading developer and manufacturer of the most advanced oral thin film drugs delivery system (CureFilm) on the market today. CURE has collaborated with top pharmaceutical firms and created several products using innovative delivery systems. CURE has established partnerships in the United States, Israel, Canada, and Germany, among other markets, to advance a variety of therapeutic categories, including pharmaceutical cannabis.

CURE Pharma Holding Corporation received patent authorization from the United States Patent and Trademark Office in November 2021 for its CUREfilm Blue Advanced technologies, an oral solubilized film of USPTO.

LTS LOHMANN Therapie-Systeme AG, a business based in Germany that specializes in creating and manufacturing drug delivery systems like oral thin films (OTF), purchased Tapemark Inc. in September 2022 for an undisclosed sum. With this acquisition, LTS took advantage of Tapemark's top CDMO, which has experience with products for iontophoresis, unit dosage semi-solid drugs, and oral thin film drugs. Tapemark Inc is a CDMO headquartered in the United States that specializes in topically applied drug delivery systems and oral thin film drugs.